(Q40684182)

22 September 2017

title

The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases (English)

1 reference

22 September 2017

Louise Tatton

1

1 reference

22 September 2017

Gary M Morley

series ordinal

2

1 reference

22 September 2017

Rajesh Chopra

series ordinal

3

1 reference

22 September 2017

Asim Khwaja

series ordinal

4

1 reference

22 September 2017

language of work or name

English

0 references

publication date

9 December 2002

1 reference

Journal of Biological Chemistry

22 September 2017

published in

1 reference

22 September 2017

volume

278

1 reference

22 September 2017

issue

7

1 reference

22 September 2017

page(s)

4847-4853

1 reference

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Evidence that Src-type tyrosine kinase activity is necessary for initiation of calcium release at fertilization in sea urchin eggs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Association of Lyn tyrosine kinase to the GM-CSF and IL-3 receptor common betac subunit and role of Src tyrosine kinases in DNA synthesis and anti-apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

The biology of stem cell factor and its receptor C-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

CHK down-regulates SCF/KL-activated Lyn kinase activity in Mo7e megakaryocytic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Lyn is activated during late G1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

Perspectives on the development of a molecularly targeted agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M209321200

21 January 2018

Identifiers

DOI

10.1074/JBC.M209321200

1 reference

22 September 2017

1 reference